4D Molecular Therapeutics (FDMT) Operating Expenses (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Operating Expenses of $76.7 million for Q1 2026, up 42.94% year-over-year from $53.6 million in Q1 2025, and up 8.94% quarter-over-quarter from $70.4 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Operating Expenses (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Operating Expenses for 7 consecutive years, with $76.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 42.94% year-over-year to $76.7 million; the TTM figure through Mar 2026 stood at $267.8 million (up 31.69% YoY), while the FY2025 annual figure was $244.8 million, up 30.27% from the prior year.
- Operating Expenses rose to $76.7 million in Q1 2026 per FDMT's latest filing, from $70.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $76.7 million in Q1 2026 and bottomed at $27.0 million in Q3 2022.
- Historically, Operating Expenses has averaged $44.5 million across 5 years, with a median of $38.2 million in 2024.
- Annual changes were most pronounced in 2023 — Operating Expenses rose 10.12% — and 2024, when it surged 53.19%.
- 4D Molecular Therapeutics' Operating Expenses stood at $30.0 million in 2022, then rose by 22.24% to $36.6 million in 2023, then soared by 53.19% to $56.1 million in 2024, then advanced by 25.41% to $70.4 million in 2025, then grew by 8.94% to $76.7 million in 2026.
- Business Quant data shows FDMT's Operating Expenses at $76.7 million in Q1 2026, $70.4 million in Q4 2025, and $61.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 80.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.81 Mn |
| Mar 31, 2026 | 76.67 Mn |
| Dec 31, 2025 | 70.38 Mn |
| Sep 30, 2025 | 61.28 Mn |
| Jun 30, 2025 | 59.47 Mn |
| Mar 31, 2025 | 53.64 Mn |
| Dec 31, 2024 | 56.12 Mn |
| Sep 30, 2024 | 51.14 Mn |
| Jun 30, 2024 | 42.46 Mn |
| Mar 31, 2024 | 38.16 Mn |
| Dec 31, 2023 | 36.63 Mn |
| Sep 30, 2023 | 34.18 Mn |
| Jun 30, 2023 | 32.38 Mn |
| Mar 31, 2023 | 30.40 Mn |
| Dec 31, 2022 | 29.97 Mn |
| Sep 30, 2022 | 27.00 Mn |
| Jun 30, 2022 | 28.59 Mn |
| Mar 31, 2022 | 27.61 Mn |
| Dec 31, 2021 | 24.86 Mn |
| Sep 30, 2021 | 24.03 Mn |